CMI’nov further expands its leadership team, naming Denis Henrard Chief Business Officer.

Monistrol sur Loire, June 1, 2020

CMI’nov is pleased to announce that Denis Henrard has joined its leadership team as Chief Business Officer, effective June 1st, 2020. He will be responsible for all business-related activities, including financing, marketing, business development and partnerships.

Bernard Pain commented: “Denis brings a wealth of global leadership experience with over 20 years in marketing and business development for Abbott Diagnostics and Ortho Mc Neil Pharmaceuticals (a Johnson & Johnson company) in the US and Becton Dickinson in France. His marketing acumen and vision, as well as success in securing financing for biotech companies, will be critical to the completion of our financing round and for future partnership discussions.”

“I am very happy to join CMI’nov’s team and help drive the completion of the preclinical and first in man program for Mit’rep, a tailor-made solution to treat mitral regurgitation”, said Denis Henrard. “Given the very high unmet medical need for this pathology, I am convinced that Mit’rep will benefit a large number of patients, many of whom have no surgical option currently.”

Mit’rep is a new generation minimally invasive annuloplasty device for the treatment of functional mitral regurgitation. Nitinol anchors delivered transapically are used to position a braid along the mitral ring, which is then used to reduce the mitral valve diameter at will, in real-time under echography.

For additional information, please contact Corinne.pain@cmi-nov.com